Prelude Capital Management’s NeuBase Therapeutics, Inc. Common Stock NBSE Stock Holding History

Prelude Capital Management’s Portfolio NBSE Stock Details NBSE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q3	–	Sell	-26	Closed	-$97K	–	2190
2014 Q2	$97K	Buy	+26	New	+$97.9K	0.01%	1105

Other funds holding NBSE

BBA

Baader Bank Aktiengesellschaft Unterschleissheim, Germany $1.33B AUM 47.35% 1-Year Est. Return

Prelude Capital Management's NBSE Position: Q2 2024 in Review

Prelude Capital Management sold out of NeuBase Therapeutics, Inc. Common Stock (NBSE) in Q2 2024, closing a stake of 15,550 shares — an estimated $7K sold.

Prelude Capital Management first reported a position in NBSE in Q3 2017 and held it in 15 quarters. The position peaked at $2.3M in Q1 2021. 3 funds tracked by Wall St. Rank hold NBSE as of Q2 2024.

Prelude Capital Management reported no remaining NeuBase Therapeutics, Inc. Common Stock position as of Q2 2024 after selling out during the quarter.
Prelude Capital Management sold 15,550 NeuBase Therapeutics, Inc. Common Stock shares in Q2 2024, an estimated $7K.
Prelude Capital Management first reported a position in NeuBase Therapeutics, Inc. Common Stock in Q3 2017 and held it in 15 quarters.
Prelude Capital Management's NeuBase Therapeutics, Inc. Common Stock position peaked at $2.3M in Q1 2021.
3 funds tracked by Wall St. Rank held NeuBase Therapeutics, Inc. Common Stock as of Q2 2024.

Based on Prelude Capital Management's 13F filing for Q2 2024, filed 14 Aug 2024.